Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

FDA Approves Second Bayer Oral Contraceptive That Also Raises Folate Levels

By Pharmaceutical Processing | December 17, 2010

Bayer HealthCare Pharmaceuticals, Inc. today announced the
FDA has approved a new oral contraceptive (OC), SAFYRALT (drospirenone 3 mg/
ethinyl estradiol 30 mcg/ levomefolate calcium 451 mcg tablets and levomefolate
calcium 451 mcg tablets). In women who choose an OC for birth control, SAFYRAL
raises folate levels for the purpose of reducing the risk of rare neural tube
defects (NTDs) in a pregnancy conceived while taking SAFYRAL or shortly after discontinuing
it. SAFYRAL provides the birth control YASMIN (drospirenone 3 mg/ ethinyl
estradiol 30 mcg)with 451 mcg levomefolate calcium, which is a B vitamin.

SAFYRAL is the second Bayer OC which contains folate. In
September, the FDA approved BeyazT (drospirenone 3 mg/ ethinyl estradiol 20
mcg/ levomefolate calcium 451 mcg tablets and levomefolate calcium 451 mcg tablets),
the first OC approved by the FDA to raise folate levels in women who choose an
OC for birth control.

“With the FDA approval of Safyral, Bayer now offers two
oral contraceptives that contain folate,” said Leslie North, Vice
President of Marketing, Women’s HealthCare, Bayer HealthCare Pharmaceuticals.

“SAFYRAL and Beyaz are part of Bayer’s growing women’s
health franchise, and these new products reinforce our commitment to providing
women various contraceptive options.”  

Related Articles Read More >

FDA logo
Ultra Supplement announces recall for undeclared tadalafil
analyzing medical sample
Expert answers to nitrosamine impurity questions
Cardinal Health
Cardinal Health announces $124M settlement of investors’ opioid suit
FDA logo
FDA warns four companies over selling honey tainted with prescription drugs

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards